Exploratory urinary metabolomics of type 1 leprosy reactions

• Main Authors: Oleg. A. Mayboroda, Anouk van Hooij, Rico Derks, Susan J.F. van den Eeden, Karin Dijkman, Saraswoti Khadge, Pratibha Thapa, Chhatra B. Kunwar, Deanna A. Hagge, Annemieke Geluk
• Format: Article
• Language: English
• Published: Elsevier 2016-04-01
• Series: International Journal of Infectious Diseases
• Subjects: Biomarkers; Diagnostics; Leprosy; Metabolomics; Reactions; Urine
• Online Access: http://www.sciencedirect.com/science/article/pii/S1201971216000321

Background: Leprosy is an infectious disease caused by Mycobacterium leprae that affects the skin and nerves. Although curable with multidrug therapy, leprosy is complicated by acute inflammatory episodes called reactions, which are the major causes of irreversible neuropathy in leprosy that occur before, during, and even after treatment. Early diagnosis and prompt treatment of reactions reduces the risk of permanent disability. Methods: This exploratory study investigated whether urinary metabolic profiles could be identified that correlate with early signs of reversal reactions (RR). A prospective cohort of leprosy patients with and without reactions and endemic controls was recruited in Nepal. Urine-derived metabolic profiles were measured longitudinally. Thus, a conventional area of biomarker identification for leprosy was extended to non-invasive urine testing. Results: It was found that the urinary metabolome could be used to discriminate endemic controls from untreated patients with mycobacterial disease. Moreover, metabolic signatures in the urine of patients developing RR were clearly different before RR onset compared to those at RR diagnosis. Conclusions: This study indicates that urinary metabolic profiles are promising host biomarkers for the detection of intra-individual changes during acute inflammation in leprosy and could contribute to early treatment and prevention of tissue damage.